Current issues in prophylactic therapy for persons with hemophilia

Acta Haematologica

Volumn 115, Issue 3-4, 2006, Pages 162-171

  Dunn, Amy L ^a,b   Abshire, Thomas C ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Arthropathy; Hemophilia; Prophylaxis

Indexed keywords

FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG INFUSION; HEALTH; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HISTORY OF MEDICINE; HUMAN; JOINT RADIOGRAPHY; NONHUMAN; OSTEOARTHRITIS; PATIENT COMPLIANCE; PLASMA; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SYNOVECTOMY; TREATMENT WITHDRAWAL;

ADOLESCENT; ADULT; CHEMOPREVENTION; CHILD; CHILD, PRESCHOOL; COAGULANTS; FACTOR IX; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS; MALE; TREATMENT OUTCOME;

EID: 33645116764     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090930     Document Type: Review

References (67)

1. Mannucci PM, Tuddenham EGD: Medical progress; the hemophilias - from royal genes to gene therapy. N Engl J Med 2001;344:1773-1779.
2. Mannucci PM, Tuddenbam EGD: The hemophilias: progress and problems. Semin Hematol 1999;36(suppl 7):104-117.
3. Nilsson IM, Hedner U, Ahlberg A: Haemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976;63:129-135.
4. Rosner F: Hemophilia in the Talmud and rabbinic writings. Ann Intern Med 1969;70:833-837.
5. Otto JC: An account of an hemorrhagic disposition existing in certain families. Med Repos 1803;6:1-9.
6. Pavlovsky A: Contribution to the pathogenesis of hemophilia. Blood 1947;2:185.
7. Biggs R, Douglas AS, Macfarlane RG, Dacie JV, Pitney WR, Merskey PMID: Christmas disease: a condition previously mistaken for haemophilia. Br Med J 1952;ii:1378-1382.
8. Farr AD: Treatment of haemophilia by transfusion: the first recorded case. J R Soc Med 1981;74:301-305.
9. Davie ER: A brief historical review of the waterfall/cascade of blood coagulation. J Biol Chem 2003;278:50819-50832.
10. Pool JG, Hershgold EJ, Pappenhagen AR: High potency antihaemophiliac factor concentrate prepared from cryoglobulin precipitate. Nature 1964;203:312.
11. Hann I, Abshire T, Lusher J, Recht M, Mathew P, Gorelick K, Charnigo R; ReFactor AF Study Group: Interim analysis of the clinic evaluation of refacto AF, a B-domain deleted recombinant FVIII (BDDrFVIII), manufactured by a novel albumin- and monoclonal antibody-free process (abstract 173). Blood 2003;102:815a.
12. Recht M, Abshire T, Lusher J, Manco-Johnson M, Gorelick K, Daly S; ReFactor AF Study Group: Results of a single-dose, randomized, double-blind, 2-period crossover pharmacokinetic study of B-domain deleted recombinant FVIII (BDDrFVIII), current manufacturing process (ReFacto), and BDDrFVIII, albumin-free manufacturing process (ReFacto AF) (abstract 2942). Blood 2003;102:53a.
13. Ewenstein B, Collins P, Shapiro A, Tarantino M, Blanchette V, Rogy S; rAHF-PFM Study Group: Global evaluation of ADVATE rAHF-PFM, an advanced category antihemophilic factor prepared using a plasma/albumin-free method. Blood 2003;102:172.
14. Hoots WK, Blanchette V, Shapiro A, Navales L, Spotts G, Togy S, Ewenstein B: Clinical evaluation of an advanced category recombinant FVIII, anti-hemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) in pediatric previously treated patients (PTPs). J Thromb Haemost 2003;164:2.
15. MASAC Recommendation #117. MASAC Recommendation Concerning Prophylaxis (Prophylactic Administration of Clotting Factor Concentrate to Prevent Bleeding). National Hemophilia Foundation, June 9, 2001.
16. Brown SA, Aledor LM; Round Table Group: Unresolved issues in prophylaxis. Haemophilia 2002;8:817-821.
17. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H: Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25-32.
18. Aledort LM, Haschmeyer RH, Pettersson H; Orthopaedic Outcome Study Group: A longitudinal study of orthopaedic outcomes for severe factor VIII deficient haemophiliacs. J Intern Med 1994;236:391-399.
19. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E: Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999;105:1109-1113.
20. Miners AH, Sabin CA, Tolley KH, Lee CA: Primary prophylaxis for individuals with severe haemophilia: how many hospital visits could treatment prevent? J Intern Med 2000;247:493-499.
21. Fischer K, Van Der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Prejs R, De Kleijn P, Grobbee DE, Van Den Berg M: The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002;99:2337-2341.
22. Schramm W: Experience with prophylaxis in Germany. Semin Hematol 1993;30(suppl 2): 12-15.
23. Van Dijk K, Fischer K, Van Der Bom JG, Mauser-Bunschoten EP, Roosendaal GK, Van Den Berg HM: Variability in bleeding pattern of severe hemophilia. Blood 2004;104:abstract 3094.
24. Ettingshausen CE, Zyschka A, Saguer IM, Heller C, Klingebiel T, Kreuz W: The role of age at first exposure and therapy regimen on the development of neutralizing FVIII antibodies in hemophilia A. Blood 2004;104:abstract 3082.
25. Santagostino E, Rocino A, Mancuso ME, Mazzucconi MG, Mancuso G, Messina M, Tagliaferri A, Luciani M, Boeri E, Mannucci PM: Impact of early factor VIII exposure, prophylaxis and prenatal/perinatal events on inhibitor risk in children with hemophilia A: a case-control study. Blood 2004;104:abstract 37.
26. Van Den Berg HM, Fischer K, Mauser-Bunschoten EP, Beek FJA, Roosendaal G, Van Der Bom JG, Nieuwenhuis HK: Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001;112:561-565.
27. Van Dijk K, Van Der Bom JG, Bax KMA, Van Der Zee DC, Van Den Berg HM: Use of implantable venous access devices in children with severe hemophilia: benefits and burden. Haematologica 2004;89:189-194.
28. Smith PS, Teutsch SM, Shaffer PA, Rolka H, Evatt B: Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. J Pediatr 1996;129:424-431.
29. Fischer K, Van Der Bom JG, Molho P, Negrier C, Mauseer-Bunschoten EP, Roosendaal G, De Kleijn P, Groggee DE, Van Den Berg HM: Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002;8:745-752.
30. Brackmann HH, Eickhoff HJ, Oldenburg J, Hammerstein U: Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience. Haemostasis 1992;22:251-258.
31. Steen Carlsson K, Hojgard S, Glomstein A, Lethagen S, Schulman S, Tengborn L, Lindgren A, Berntorp E, Lindgren B: On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003;9:555-566.
32. Gringeri A: Long-term aspects of hemophilia B treatment. Part II. Blood Coagul Fibrinolysis 2004;15(suppl 2):S15-S16.
33. Fischer K, Astermark J, Van Der Bom JG, Ljung R, Berntorp E: Prophylactic treatment for severe haemophilia: Comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002;8:753-760.
34. Fischer K, Van Den Berg M: Prophylaxis for severe haemophilia: clinical and economical issues. Haemophilia 2003;9:376-381.
35. Bjorkman S, Berntorp E: Pharmacokinetics of coagulation factors clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001;40:815-832.
36. Blanchette V, Shapiro AD, Liesner R, Hernandez F, Retzios AD, Schroth P, Fritsch S, Spotts G, Ewenstein BM: Characterization of the pharmacokinetics of rFVIII in young pre-school children with hemophilia, including an analysis of the influence of age and body weight. Blood 2004;104:abstract 3084.
37. Carlsson M, Berntorp E, Bjorkman S, Lethagen S, Ljung R: Improving cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 1997;3:96-101.
38. Blanchette VS, Rivard GE, Israels SJ, Robinson KS, Babyn PS, McLimont MJ, Hilliard PE, Feldman BM: Musculoskeletal results from the Canadian hemophilia dose-escalation prophylaxis trial; in Abstracts of the American Society of Hematology 45th Annual Meeting and Exposition, San Diego, Calif. 2003, p 171.
39. Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B: When should prophylactic treatment in patients with haemophilia A and B start? - The German experience. Haemophilia 1998;4:413-417.
40. Petrini P, Lindvall N, Egberg N, Blomback M: Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol 1991;13:280-287.
41. Leisner RJ, Khair K, Hann IM: The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996;92:973-978.
42. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R: Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994 47:113-117.
43. Arnold WD, Hilgartner MW: Hemophilic arthopathy. J Bone Joint Surg Am 1977;59:287-305.
44. Pettersson H, Ahlberg A, Nilsson IM: A radiologic classification of hemophilic arthropathy. Clin Orthop 1980;149:153-159.
45. Nuss R, Kilcoyne F, Geraghty S, Shroyer ALW, Rosky JW, Mawhinney S, Wiedel J, Manco-Johnson M: MRI findings in haemophilic joints treated with radiosynoviorthesis with development of an MRI scale of joint damage. Haemophilia 2000;6:162-169.
46. Kilcoyne RF, Nuss R: Radiological assessment of haemophilic arthropathy with emphasis on MRI findings. Haemophilia 2003;9(suppl 1): 57-64.
47. Lundin B, Pettersson H, Ljung R: A new magnetic resonance imaging scoring method for assessment of haemophilic arthropathy. Haemophilia 2004;10:383-389.
48. Blanchette VS, Mccready M, Achonu C, Abdolell M, Rivard G, Manco-Johnson MJ: A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centers. Haemophilia 2003;9(suppl 1):19-26.
49. Srivastava A: Choice of factor concentrates for haemophilia: a developing world perspective. Haemophilia 2001;7:117-122.
50. Tussell J, Perez-Bianco R: Prophylaxis in developed and in emerging countries. Haemophilia 2002;8:183-188.
51. Panicker J, Warrier I, Thomas R, Lusher JM: The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003;9:272-278.
52. Shapiro AD: Why is primary prophylaxis underutilized in the United States? Haemophilia 2003;9:670-672.
53. Butler RB, McClure W, Wulff K: Practice patterns in haemophilia A therapy - a survey of treatment centres in the United States. Haemophilia 2003;9:549-554.
54. Hacker MR, Geraghty S, Manco-Johnson M: Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001;7:392-396.
55. Butler RB: Clinical convenience of low volume FVIII infusions in pediatric hemophilia patients. Hemaware 2004;10:114.
56. Bollard CM, Teague LR, Berry EW, Ockelford PA: The use of central venous catheters (portacaths) in children with haemophilia. Haemophilia 2000;6:66-70.
57. Ljung R, van den Berg M, Petrini P, Tengborn L, Scheibel E, Kekomaki R, Effenberger W: Port-a-cath usage in children with haemophilia: experience of 53 cases. Acta Paediatr 2004;87:1051-1054.
58. Perkins JL, Johnson VA, Osip JM, Christie BA, Nelson SC, Moertel CL, Heisel MA: The use of implantable venous access devices (IVADs) in children with hemophilia. J Pediatr Hematol Oncol 1997;19:339-344.
59. Miller K, Buchanan GR, Zappa S, Cochran C, Laufenberg J, Medeiros D, Sanders J: Implantable venous access devices in children with hemophilia: a report of low infection rates. J Pediatr 1998;132:934-938.
60. Liesner RJ, Vora AJ, Hann IM, Lilleymann JS: Use of central venous catheters in children with severe congenital coagulopathy. Br J Haematol 1995;91:203-207.
61. Srivaths PR, Rozans MK, Kelly E, Venkateswaran L: Bacillus cereus central line infection in an immunocompetent child with hemophilia. J Pediatr Hematol Oncol 2004;26:194-196.
62. Santagostino E, Gringeri A, Muca-Perja M, Mannucci PM: A prospective clinical trial of implantable central venous access in children with haemophilia. Br J Haematol 1998;102:1224-1228.
63. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM: Central venous access devices in haemophilia. Haemophilia 2004;10:134-146.
64. Journeycake JM, Quinn CT, Miller KL, Zajac JL, Buchanan GR: Catheter-related deep venous thrombosis in children with hemophilia. Blood 2001;98:1727-1731.
65. Price VE, Carcao M, Connolly B, Chait P, Daneman A, Temple M, Stain AM, Sung L, Al-Tralbbosi H, Blanchette VS: A prospective, longitudinal study of central venous catheter-related deep venous thrombosis in boys with hemophilia. J Thromb Haemost 2004;2:737-742.
66. Hooiveld MJ, Roosendaal G, Vianen ME, van den Berg HM, Bijlsma JW, Lafeber FP: Immature articular cartilage is more susceptible to blood-induced damage than mature articular cartilage: an in vivo animal study. Arthritis Rheum 2003;48:396-403.
67. Fischer K, Van Der Bom JG, Prejs R, Mauser-Bunschoten EP, Roosendaal G, Grobbee DE, Van Den Berg HM: Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects of outcome. Haemophilia 2001;7:544-550.